Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Nektar Therapeutics (NKTR) had Stock-Based Compensation of $6.72M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$10.13M |
|
$-40.62M |
|
-- |
|
$10.13M |
|
$52.47M |
|
$-42.34M |
|
$2.04M |
|
$-40.30M |
|
$-40.30M |
|
$-40.30M |
|
$-40.62M |
|
$-40.62M |
|
$-40.30M |
|
$-42.34M |
|
$-45.76M |
|
33.05M |
|
33.05M |
|
$-1.23 |
|
$-1.23 |
|
| Balance Sheet Financials | |
$739.40M |
|
-- |
|
$355.73M |
|
$1.10B |
|
$70.98M |
|
-- |
|
$121.02M |
|
$192.01M |
|
$903.12M |
|
$903.12M |
|
$903.12M |
|
34.13M |
|
| Cash Flow Statement Financials | |
$-120.07M |
|
$-749.90M |
|
$894.12M |
|
$15.12M |
|
$39.27M |
|
$24.15M |
|
|
Stock-Based Compensation |
$6.72M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.42 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-417.94% |
|
-417.94% |
|
-- |
|
-397.80% |
|
-400.97% |
|
$-120.18M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-4.50% |
|
-4.50% |
|
-3.71% |
|
-4.50% |
|
$26.46 |
|
$-3.64 |
|
$-3.63 |
|